OSE Immunotherapeutics Adds Boehringer Ingelheim To Its Pharma Partnering List

 
• By Sten Stovall

Collaborating with the German family-controlled drug maker on OSE's novel checkpoint inhibitor aligns with French firm's strategy of partnering its portfolio candidates.

Laboratory
OSE and BI To Start OSE-172 Phase I Trials In Early 2019 • Source: Shutterstock

More from Strategy

More from Business